
2024 was a monumental year for HeartLung Technologies. With that being said, we have exciting developments coming up in 2025!
In this year-in-review, we highlight the key milestones and achievements that have propelled HeartLung Technologies (www.heartlung.ai), as a leading developer of innovative AI-enabled solutions for early detection of heart disease, lung cancer, osteoporosis, fatty liver disease and other fatal conditions using standard CT scans, to the forefront of preventive healthcare. Our advancements in AI-driven diagnostics and early detection tools have set new standards, and we are excited to lead the way and share our ambitious goals for 2025 with the healthcare community.
Scientific Publications from 2024
This study published in Nature (NPJ Digital Medicine) highlights the transformative potential of AI in advancing coronary artery calcium scans by extracting additional information that was not used before. AI-CAC drastically improved on the predictive value of the traditional Agatston score for prediction of CVD.
In this study, HeartLung Technologies has demonstrated that AI-enabled left atrial volumetry in coronary artery calcium (CAC) scans can predict atrial fibrillation (AF) as early as one year in advance. This innovative approach provides more actionable information than traditional CAC score, significantly improving early detection and patient outcomes
In this study, we demonstrated that our AI-enabled automated volumetry of cardiac chambers, known as AutoChamber™, which works on non-contrast coronary artery calcium (CAC) scans and well as contrast-enhanced coronary CT angiography (CCTS), predicts heart failure and offers a promising tool for flagging patients prior to developing heart failure, enhancing preventive care.
In this study, AI-CAC™ predicted atrial fibrillation and stroke with accuracy comparable to cardiac magnetic resonance imaging (MRI). This breakthrough provides a more accessible and cost-effective alternative to MRI significantly enhancing preventive care for cardiovascular diseases.
SCCT, ESC, AHA, RSNA: 2024 Exhibits and Scientific Presentations
During the 2024 annual scientific meeting of the Society of Cardiovascular Computed Tomography (SCCT), HeartLung Technologies showcased their research on AI-CAC™ and AI-CVD™. These studies demonstrate the power of AI in identifying and forecasting cardiovascular diseases, setting the stage for more personalized and preventive healthcare.
HeartLung Technologies presented seven groundbreaking AI-enabled research studies at the Annual Congress of the European Society of Cardiology (ESC) 2024 in London. These studies showcase the innovative applications of AI in cardiology, offering new insights into CVD prevention.
At the Annual Scientific Sessions of the American Heart Association 2024, HeartLung Technologies presented research studies on AI-CAC™ and AI-CVD™. These studies highlight the effectiveness of AI in detecting and predicting cardiovascular diseases, paving the way for more personalized and preventive care.
At the RSNA 2024, HeartLung Technologies presented four groundbreaking scientific research studies on AI-CAC™, AutoBMD™, and AI-CVD™. These studies demonstrated the potential of AI in improving early detection technologies and patient outcomes.
In collaboration with I-ELCAP (The International Early Lung Cancer Action Program), HeartLung Technologies and SHAPE began showcasing video presentations from the first conference focused on integrating early heart and lung disease detection through low-dose CT. The 3-day event featured video presentations from leading experts in the field, highlighting the latest advancements and research in preventive cardiology.
Dr. Claudia Henschke, a distinguished advisor to HeartLung Technologies and a pioneer in lung cancer screening, was honored with the RSNA 2024 Scientific Excellence Award. Her contributions to the field have been instrumental in advancing early detection and improving patient outcomes.
FDA Breakthrough Designation
In 2024, HeartLung Technologies achieved a significant milestone by receiving the first and only FDA designated “Breakthrough” AI for opportunistic detection of heart disease in CT scans that is invisible to human eyes. This Breakthrough AI is designed to take advantage of existing information in CT scans providing healthcare professionals with a powerful tool for early detection and treatment of heart disease.
Pipeline for 2025
As we look ahead to 2025, HeartLung Technologies is committed to our mission of advancing personalized preventive medicine powered by AI. Our pipeline for this year includes scientific publications on the predictive value of AI-CVD components as well as securing FDA approval for AI-CVD so hospitals and diagnostic imaging centers can offer AI-enabled cutting-edge early detection technology to their patients.
HeartLung seeks FDA approval for all elements of AI-CVD™
Looking Forward: Embracing Innovation in Personalized Preventive Medicine
As we reflect on the remarkable achievements of 2024, we are filled with pride and gratitude for the dedication and innovation demonstrated by our team at HeartLung Technologies. This past year has been a testament to our commitment to advancing the field of personalized preventive medicine through cutting-edge AI technologies and collaborative research efforts.
In 2025, we are poised to build on this momentum with an ambitious pipeline of goals that will further enhance our capabilities and expand our reach. From the integration of predictive analytics into AI-CVD™, and the development of a comprehensive pooled cohorts model that would outperform existing risk-factors based risk prediction scores. These efforts are geared towards averting preventable death due to CVD and other fatal conditions thereby transforming healthcare from reactive medicine and sick care to proactive medicine and health care.
We invite you to join us on this exciting journey. Whether you are a healthcare professional, researcher, or patient advocate, your support and collaboration are invaluable to our mission. Together, we can drive innovation, foster early detection, and ultimately save lives.
Stay connected with us through our website and social media channels for the latest updates on our projects and initiatives. We look forward to sharing more groundbreaking advancements with you this year.
Thank you for being a part of the HeartLung Technologies community. Here's to a future of healthier hearts and lungs!

HeartLung uses AI for early detection of heart disease, lung cancer, osteoporosis, fatty liver, and other fatal conditions. HeartLung received FDA "Breakthrough Designation” for AutoChamber™ AI that detects enlarged cardiac chambers and left ventricular hypertrophy in non-contrast chest CT scans which are invisible to human eyes. HeartLung cleared FDA 510(k) for AutoBMD™, which is the only DEXA-equivalent, CT-based opportunistic osteoporosis screening approved by the FDA that is applicable to 25+ million CT scans every year and is reimbursed by Medicare. HeartLung is awaiting approval for AI-CVD™, which includes multiple AI modules, including AI-CAC™ (AI-enabled Coronary Artery Calcium Scoring), focusing on opportunistic screening in chest CT scans. For more information, visit www.heartlung.ai/knowledge-center and email contact@heartlung.ai.
Comments